AMLX vs CNS: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AMLX (Amylyx Pharmaceuticals) and CNS (Cohen & Steers) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
AMLX vs CNS: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AMLX | CNS | What it tells you |
|---|---|---|---|
| Market cap | $3.48B | $3.85B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -25.40 | 20.05 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | -0.08 | 1.18 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 56% of range | 59% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 12.90 | 6.34 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AMLX and CNS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMLX and CNS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMLX and CNS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Amylyx Pharmaceuticals (AMLX) do?
Amylyx Pharmaceuticals develops treatments for neurodegenerative and endocrine conditions with few or no approved options. Its lead program is avexitide, a GLP-1 antagonist being tested in adults with post-bariatric hypoglycemia (PBH), a condition where people who have had Roux-en-Y gastric bypass surgery experience severe blood-sugar crashes. The registrational Phase 3 LUCIDITY trial enrolled 78 participants across a 16-week blinded period and met its pre-specified primary endpoint: a 55% reduction in Level 2 and Level 3 hypoglycemic events (p=0.000003). It also met secondary endpoints on Level 2 events, Level 3 events, and continuous glucose-monitoring outcomes, and avexitide was generally safe and well tolerated, consistent with earlier trials. All eligible patients moved into the open-label extension. Amylyx plans to present the topline data at ObesityWeek 2026 and to submit a New Drug Application before year-end 2026, with management discussing a possible 2027 launch. Behind it sit AMX0035 in Wolfram syndrome (a focused registrational Phase 3 was guided for the second half of 2026 after extended Phase 2 HELIOS data showed trends in pancreatic function and vision stabilization), AMX0114 in ALS (Phase 1 LUMINA data reported as safety-supportive), and AMX0318 in IND-enabling studies.
What does Cohen & Steers (CNS) do?
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT), which in October 2026 bought the Manchester Village Shopping Center in Rock Hill, South Carolina.
AMLX vs CNS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AMLX drivers: From LUCIDITY data to an FDA filing; A market with no approved therapy.
- CNS drivers: Interest rates and real assets; Return to organic growth.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The concentration risk remains the dominant one: avexitide now carries nearly all of the equity value, and a positive 78-patient trial still leaves FDA review risk, label risk, and the possibility of requests for more data. For CNS, cNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings.
AMLX or CNS: which should you pick?
AMLX vs CNS: the full fundamentals
AMLX. Standard valuation multiples do not apply here because there is no revenue and no path to profitability without an approval. After the positive LUCIDITY result, the market capitalization of about $3.35 billion (October 16, 2026) sits on top of about $251 million of cash and a trailing loss near $152 million, so most of the value is the market's view of avexitide's approval odds and launch potential. The 11 analysts covering the stock have an average target near $43, and the Q3 2026 report on November 5 will update the cash line and filing timeline.
CNS. As of mid-October 2026, CNS trades at about 21 times trailing and 19 times forward earnings with a dividend yield near 3.9%, a little cheaper than in the spring after the shares pulled back from their 52-week high of about $86.56. The third quarter showed revenue growth holding at about 11% with margins intact, so the debate is less about the quarter and more about whether higher bond yields keep pressing on AUM. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.
Headline figures (approximate, October 2026): AMLX shows product revenue None (Relyvrio withdrawn in 2024; consensus ~$28M for 2027), cash and equivalents ~$250.8M (June 30, 2026), cash runway Guided into 2028, net loss (ttm) ~$152M (EPS ~-$1.41); CNS shows revenue (ttm) ~$600M, +11% YoY in Q3 2026, revenue (q3 2026) ~$157.4M, adjusted eps (q3 2026) ~$0.89, roughly in line with consensus, net income (ttm) / net margin ~$169M / ~28%.
The bottom line: AMLX vs CNS
AMLX and CNS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMLX and CNS exposure against your real portfolio. It is not an investment adviser.
Wondering how AMLX or CNS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Amylyx Pharmaceuticals with AI
Connect the broker you already use and ask Walnut's AI how AMLX fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between AMLX and CNS?
+
Amylyx Pharmaceuticals develops treatments for neurodegenerative and endocrine conditions with few or no approved options. Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AMLX or CNS the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AMLX or CNS?
+
On forward P/E (as of November 2026), AMLX trades at -25.40x and CNS at 20.05x, so AMLX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AMLX and CNS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AMLX vs CNS?
+
AMLX: The concentration risk remains the dominant one: avexitide now carries nearly all of the equity value, and a positive 78-patient trial still leaves FDA review risk, label risk, and the possibility of requests for more data. Amylyx has already failed a confirmatory Phase 3 once, with Relyvrio withdrawn from the market in 2024, so execution credibility is still being rebuilt. Launching a drug for a rare condition is costly, and adoption depends on endocrinologists and payers treating the effect size as a clear improvement over cheap off-label options. The company generates no product revenue and lost about $152 million over the trailing twelve months, so any delay pushes it toward a financing that would dilute existing holders. The stock is volatile: it more than tripled from its 52-week low of $10.83 to $41.14 and then fell about 18% in the month to October 16, 2026, and an insider sold about $831,000 of shares in early October. There is also a legacy legal item: a securities class action tied to 2022 to 2023 Relyvrio launch statements was settled for $6.5 million, with preliminary court approval in May 2026 and a final approval hearing scheduled for September 2026. CNS: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. Its concentration in real estate and rate-sensitive income means a reversal to higher-for-longer rates, or a rotation away from REITs and preferreds, could trigger outflows and market depreciation at the same time; the AUM declines reported for August and September 2026 show that dynamic at work. EPS has come in slightly below consensus in three of the last four quarters. The dividend absorbs about 79% of trailing earnings, which leaves less cushion if profits dip. The active-management fee model faces secular pressure from low-cost passive and index products, and net flows can turn negative in stressed markets. Newer private and non-traded initiatives add execution and liquidity risk, and results can be lumpy quarter to quarter.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMLX or CNS; figures are approximate and dated (as of November 2026). Verify current data before investing.